Novo Nordisk launches "robust" Hispanic FlexPen play

Share this article:
Novo Nordisk launches "robust" Hispanic FlexPen play
Novo Nordisk launches "robust" Hispanic FlexPen play
Novo Nordisk has launched a big integrated Spanish-language marketing campaign for its FlexPen insulin delivery device – one that Univision calls “the most robust ever” in Hispanic media for the diabetes sector.

“It's a portfolio play across all our brands,” said Novo Nordisk's Jeremy Shepler, associate director of marketing. “What we learned that initiated this effort was that the prevalence of type 2 diabetes among Hispanics is quite large, 2.4 times greater than among non-Hispanic whites. We also know this population is projected to increase 25% over the next twenty years.”

A tracking survey the company ran found a scant 9% unaided awareness of insulin delivery devices among Hispanics with diabetes. Among insulin users, awareness was scarcely higher at 15%.

FlexPen straddles Novo Nordisk's insulin portfolio, which includes the Novolog and Levemir brands. The TV component, with ads airing on channels including Univision, Telemundo and Telefutura, is specific to Novolog FlexPen, but other parts, including online promotion, will plug both brands. Cult Health handled creative in partnership with Miami-based Hispanic marketing specialist DMG Solutions.

The tagline is “Administracion de insulina que va contigo – in English, “Insulin delivery that's going places.” The tagline for English-language ads is “Insulin delivery my way.”  

Digital efforts go beyond banner ads, with a website (miflexpen.com), relationship marketing and paid search.

“Understanding the 12.3% diabetes prevalence rate for Hispanics versus 8.4% for non-Hispanics and the tremendous opportunity to reach a consumer that can drive demand for their product,  FlexPen has taken a strategic approach to engage with  the Latino consumer directly in Spanish,” said Jorge Daboub, VP for Univision's Client Development Group. “This is the most robust diabetes campaign ever targeting Hispanic Americans and it is the first integrated DTC campaign leveraging both TV and digital media.”

“To have something so integrated across languages is new,” said Shepler, “and it's not just a one off initiative. It's integrated in to a bigger play.”

A recent Univision study of predominately Spanish-speaking American patients found a need for more in-culture communications about health and medicine, noting that Hispanics are 21% less likely to be diagnosed with disease than non-Hispanics.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...